FDA Investigator Rodney T Allnutt
Rodney T Allnutt has inspections in 1 countries as of 21 Aug 2023. Rodney T Allnutt has collaborated with a combined 793 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
21 Aug 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
United States of America
Co-Investigator(s):
Allen F Hall,
Allen Lou,
Barbara M Frazier,
Byungja E Marciante,
Charles J Chacko,
Cheryl A Grandinetti,
Christina N Maurino,
Deborah B Nixon,
Denise M Visco, Investigator,
Douglas C Kovacs,
Emmanuel J Ramos,
Eric Rothschild,
Erin D Mccaffery,
Ernest A Clausnitzer,
George Pyramides,
Guerlain Ulysse,
Iris C Macinnes,
James R Fleckenstein,
Jean M Kelahan,
Joan A Loreng,
Karen E D'orazio,
Kassa Ayalew, MD,
Kirtida Patel,
Lata C Mathew, PhD,
Leonard H Lavi,
Liatte Kreuger, PharmD,
Lisa Harlan,
Matthew A Spataro,
Mayar M Mussa,
Melissa T Roy,
Michael Serrano,
Nina Yang,
Paul L Bellamy,
Peter R Lenahan,
Regina T Brown,
Robert W Jennings,
Shari H Shambaugh,
Shari J Hamilton,
Stephanie E Hubbard,
Stephanie T Durso,
Tonia F Bernard,
Tyanna N Hadley,
Tynna N Hadley,
Wr Bowman,
Yvesna C Blaise
Rodney T Allnutt's Documents
Publish Date | Document Type | Title |
---|---|---|
August, 2000 | EIR | University of South Florida-Division of Comparative Medicine - EIR, 2000-08-04 |
May, 2003 | FDA 483 Response | American Cardiovascular Res Ins - Form 483R, 2003-06-06 |
June, 2004 | FDA 483 | Novartis Pharmaceuticals Corporation - Form 483, 2004-06-10 |
May, 2003 | FDA 483 | American Cardiovascular Res Ins - Form 483, 2003-05-09 |
May, 2003 | EIR | American Cardiovascular Res Ins - EIR, 2003-05-09 |
February, 2001 | FDA 483 | Mentor Worldwide LLC - Form 483, 2001-12-06 |
June, 2004 | EIR | Novartis Pharmaceuticals Corporation - EIR, 2004-06-10 |
August, 2000 | FDA 483 | University of South Florida-Division of Comparative Medicine - Form 483, 2000-08-04 |
June, 2004 | FDA 483 Response | Novartis Pharmaceuticals Corporation - Form 483R, 2004-07-02 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more